Our Investigators

Chairman's Office

Jay S. Skyler, M.D., Type 1 Diabetes TrialNet Chairman, University of Miami
Distinguished career in diabetes that spans more than four decades that includes founding and leading the University of Miami's Diabetes Metabolic Unit to international prominence.

Lisa E. Rafkin, MS, RD, CDE, Type 1 Diabetes TrialNet, University of Miami
Coordinates study-wide operations between the University of Miami's Diabetes Research Institute, NIH, and the Type 1 Diabetes TrialNet Coordinating Center.

Jay Sosenko, M.D., Type 1 Diabetes TrialNet Associate Chair for Epidemiology and Ethics, University of Miami
Primary author of a paper that was the first to show an association between diabetic sensory neuropathy and height.

Norma S. Kenyon, Ph.D., Type 1 Diabetes TrialNet Associate Chair for Immunology

NIDDK

Ellen Leschek, M.D., Type 1 Diabetes TrialNet Program Director, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases
Pediatric endocrinologist, clinical researcher, and clinical research director who provides scientific and managerial oversight to Type 1 Diabetes TrialNet and its multi-center studies.

Lisa Spain, Ph.D. Program Director for Autoimmune Endocrine Diseases, Division of Diabetes, Endocrinology & Metabolism, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Molecular and Cellular Immunologist, provides scientific and managerial oversight for mechanistic and laboratory activities within Type 1 Diabetes TrialNet and its multi-center studies.

Australia

John M. Wentworth, M.D., Type 1 Diabetes Principal Investigator, Walter and Eliza Hall Research Institute. Responsible for the Natural History Study and Oral Insulin Study in subjects at risk for new onset type 1 diabetes. Heads the network of TrialNet clinical sites in Australia.

California

Bruce A. Buckingham, M.D., Type 1 Diabetes TrialNet Co-Investigator, Stanford University School of Medicine
Renowned diabetes researcher whose primary focus is on diabetes research in children, particularly continuous glucose monitoring and immune intervention for the treatment of type 1 diabetes.

Stephen E. Gitelman, M.D., Type 1 Diabetes TrialNet Principal Investigator, University of California San Francisco Children's Hospital
Pediatric endocrinologist and diabetes researcher who is working with scientists around the world to create new treatments to block autoimmune destruction of insulin-producing beta cells, improve current treatments, and ultimately prevent the disease.

Darrell Wilson, M.D., Type 1 Diabetes TrialNet Principal Investigator, Stanford University
Expansive career in pediatric endocrinology and diabetes includes current position as the Chief of Pediatric Endocrinology and Diabetes at the Lucile Packard Children's Hospital at Stanford.

Colorado

Peter Gottlieb, M.D., Type 1 Diabetes TrialNet Principal Investigator, University of Colorado at Denver

Connecticut

Kevan C. Herold, M.D., Type 1 Diabetes TrialNet Principal Investigator, Yale University School of Medicine
Well known in the field of type 1 diabetes research for being part of the team that was the first to report use of anti-CD3 monoclonal antibody, a treatment now in development.

Florida

Jennifer B. Marks, M.D., Type 1 Diabetes TrialNet Principal Investigator, University of Miami, Miller School of Medicine
Endocrinologist/diabetologist who sees patients, teaches, and conducts clinical research in several areas of diabetes, including prevention, treatment, and prevention of complications.

Desmond Schatz. M.D., Type 1 Diabetes TrialNet Principal Investigator, University of Florida College of Medicine
Well-known and published pediatric endocrinologist involved in type 1 diabetes research with a focus on the prediction, natural history, genetics, immunopatho-genesis and prevention of type 1 diabetes, as well as the management of type 1 diabetes in children and adolescents.

Indiana

Linda A. DiMeglio, MD, MPH, Type 1 Diabetes TrialNet Principal Investigator, Indiana University School of Medicine
Associate Professor of Pediatrics, Department of Pediatrics, Section of Pediatric Endocrinology/Diabetology, Riley Hospital for Children, Indiana University School of Medicine

Italy

Emanuele Bosi, M.D., Type 1 Diabetes Principal Investigator, San Raffaele Hospital

Responsible for the Natural History Study and Oral Insulin Study in subjects at risk for new onset type 1 diabetes. Heads the network of TrialNet clinical sites in Italy and Germany.

Minnesota

Antoinette Moran, M.D., Type 1 Diabetes TrialNet Regional Principal Investigator, University of Minnesota
Highly published author on diabetes complications, who specializes in clinical trials to prevent or delay the onset of type 1 diabetes; co-directs the assessment of metabolic endpoints to improve the efficacy of islet transplantation of type 1 diabetes.

New York

Robin Goland, M.D., Type 1 Diabetes TrialNet Principal Investigator, Columbia University
Noted clinical investigator who is part of the team who established the Naomi Berrie Diabetes Center and has guided it to a premier, family-focused diabetes care and research facility.

Ontario, Canada

Diane Wherrett, MD, FRCPC, Type 1 Diabetes Principal Investigator. Chair of GAD New Onset Trial, Vice-Chair GAD Prevention Trial, Chair of Eligibility Committee, Vice-Chair of Ancillary Studies Committee.

Endocrinologist and Associate Professor in the Department of Pediatrics for The Hospital for Sick Children, University of Toronto. Heads the Canadian network of TrialNet clinical sites.

Pennsylvania

Dorothy J. Becker, MBBCh, Type 1 Diabetes TrialNet Principal Investigator and Regional Coordinator, Children's Hospital of Pittsburgh
International speaker and recognized expert in the treatment and prevention of diabetes in children.

Tennessee

William E. Russell, M.D., Type 1 Diabetes TrialNet Principal Investigator, Vanderbilt Eskind Diabetes Clinic.

Texas

Philip Raskin, M.D., Type 1 Diabetes TrialNet Principal Investigator, University of Texas Southwestern Medical Center
Clinical researcher widely renowned for his work in diabetes, diabetes complications, and diabetes management.

Turku, Finland

Olli Simell, M.D., Type 1 Diabetes TrialNet Principal Investigator, University of Turku, Turku, Finland
Physician, researcher, and instructor of international stature, and member of a dozen Finnish and international scientific advisory and review boards.

United Kingdom

Penelope Bingley, M.D., Type 1 Diabetes Principal Investigator, University of Bristol. Member of TN01 Natural History Study Chair Committee and Chair of Dried-Blood Spot Ancillary Study Committee. Professor of Diabetic Medicine at the University of Bristol and Honorary Consultant Physician at Southmead Hospital and Bristol Royal Infirmary, Bristol. Heads the network of TrialNet clinical sites in the United Kingdom.

Washington

Carla Greenbaum, M.D., Type 1 Diabetes TrialNet Principal Investigator and Vice Chair, Benaroya Research Institute
Leader in clinical investigations and trials to prevent or intervene with the diabetes autoimmune process and well-known as an expert in designing research protocols for children with diabetes.